Biograph 64 truepoint truev

Manufactured by Siemens

Sourced in Germany

The Biograph 64 TruePoint TrueV is a medical imaging device designed for PET/CT (Positron Emission Tomography/Computed Tomography) scanning. It combines high-resolution PET and CT technologies to provide comprehensive diagnostic imaging capabilities.

Automatically generated - may contain errors

Lab products found in correlation

Cti rds 111, by Siemens (4 mentions) Biograph 64, by Siemens (2 mentions) Polestar m660, by Siemens (2 mentions) Discovery 690, by GE Healthcare (2 mentions) Achieva dstream whole body scanner, by Philips (1 mentions)

Close spelling variants of this product

Biograph 64 TruePoint TrueV PET/CT system Biograph 64 TruePoint with TrueV Biograph 64 Truepoint TrueV PET/CT scanner Biograph 64 TrueV Biograph TruePoint 64 Biograph TrueV Biograph Truepoint Biograph 64

12 protocols using biograph 64 truepoint truev

Myocardial Energy Substrate Profiling via 11C-Acetate PET

Check if the same lab product or an alternative is used in the 5 most similar protocols

All participants underwent an ¹¹C‐acetate PET scan on a Siemens Biograph TruePoint TrueV 64 PET/computed tomography scanner. A catheter was placed in an antecubital vein, and after a minimum rest of 30 minutes, venous blood was collected for analysis of myocardial energy substrates: free fatty acids, glucose, ketone bodies (3‐hydroxybutyrate), and lactate. Levels of N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP), hemoglobin, insulin, and catecholamine metabolites (metanephrine and normetanephrine) were also analyzed. Subsequently, 400 MBq ¹¹C‐acetate was injected, followed by list‐mode PET recordings for 27 minutes. Heart rate and blood pressure were measured at 5, 10, and 20 minutes after injection.
Reconstruction of dynamic images and attenuation correction were performed according to a previously described method.14 Dynamic data sets were analyzed using the software package Cardiac VUer, as previously described.18 Image‐derived arterial input function was obtained automatically and corrected for metabolites.18, 19 The average time–activity curve of the entire left ventricle was obtained and fitted to a 1‐tissue compartment model yielding the global clearance rate (k₂) of activity from the myocardium.20, 21 Myocardial blood flow was estimated using the global uptake rate K₁, corrected for the incomplete extraction of ¹¹C‐acetate.22

Hansson N.H., Sörensen J., Harms H.J., Kim W.Y., Nielsen R., Tolbod L.P., Frøkiær J., Bouchelouche K., Dodt K.K., Sihm I., Poulsen S.H, & Wiggers H. (2017). Myocardial Oxygen Consumption and Efficiency in Aortic Valve Stenosis Patients With and Without Heart Failure. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 6(2), e004810.

+ Open protocol

+ Expand

Cardiac Metabolism Assessment by 11C-Acetate PET

Check if the same lab product or an alternative is used in the 5 most similar protocols

An ¹¹C‐acetate PET scan was performed in all subjects in the resting state on a Siemens Biograph TruePoint TrueV 64 PET/CT scanner. We placed a catheter in an antecubital vein. The subjects rested for a minimum of 30 minutes. Subsequently, ¹¹C‐acetate (5 MBq/kg) was injected followed by a 27‐minute list mode PET recording. The heart rate and arterial blood pressure was measured by sphygmomanometer at 5, 10, and 20 minutes after injection.
Reconstruction of dynamic images was performed as described in a previous paper from our group.18 The aQuant software package was used for dynamic data sets analysis using automatically obtained image‐derived and metabolites‐corrected arterial input functions.19 The average LV time‐activity curve was obtained and fitted into a 1‐tissue compartment model yielding the global myocardial clearance rate (k₂).20, 21 MBF was estimated using the global uptake rate (K₁), which was corrected for the incomplete extraction of ¹¹C‐acetate.22 MVO₂ (mL/min per gram) was calculated from k₂ as MVO₂=(135×k₂−0.96)/100.20CO was calculated using the indicator‐dilution principle and the arterial input functions. In addition, LV mass was obtained from the dynamic data set using parametric images and contour detection, as described in detail elsewhere.21

Clemmensen T.S., Soerensen J., Hansson N.H., Tolbod L.P., Harms H.J., Eiskjær H., Mikkelsen F., Wiggers H., Andersen N.F, & Poulsen S.H. (2018). Myocardial Oxygen Consumption and Efficiency in Patients With Cardiac Amyloidosis. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 7(21), e009974.

+ Open protocol

+ Expand

11C-acetate PET Imaging of Cardiac Metabolism

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

A total of 400 MBq 11C-acetate was injected, followed by list-mode PET recording for 27 minutes on a Biograph TruePoint TrueV 64 PET/computed tomography scanner (Siemens, Germany). Blood pressure and HR were measured at 1, 5, 10, and 20 minutes after injection. The examination was performed to obtain the global clearance rate (k₂) and to calculate MVO₂ as previously described:^{11 (link)}Dynamic data sets were analyzed to estimate SV by use of aQuant Research.^{12 (link)} HR and MAP were measured noninvasively. Left ventricular mass and CO were obtained from the PET dataset, and MEE was calculated as:^{13 (link)}MBF (mL · g^-1 · min^-1) was estimated by measuring k₁ and correcting for rate pressure product as previously described.^{14 (link)} The assessor of the PET examinations was blinded to treatment allocation and group.

Nielsen R., Møller N., Gormsen L.C., Tolbod L.P., Hansson N.H., Sorensen J., Harms H.J., Frøkiær J., Eiskjaer H., Jespersen N.R., Mellemkjaer S., Lassen T.R., Pryds K., Bøtker H.E, & Wiggers H. (2019). Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation, 139(18), 2129-2141.

+ Open protocol

+ Expand

PET and Cardiac MRI Protocol for Myocardial Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols

PET. 11 C-acetate was synthesized according to the method of Pike et al. (13) , with minor in-house modifications. All subjects were instructed to fast for at least 4 h before undergoing PET, except for water and medicine prescribed for daily intake. Using a Biograph TruePoint TrueV 64 PET/CT scanner (Siemens GMBH), a low-dose CT scan (120 kV, 30 mAs, 4-mm slice thickness) was obtained, followed by a 27-min list-mode emission scan that began simultaneously with automated bolus injection of 407 6 30 MBq of 11 C-acetate (1 mLÁs 21 ) followed by a 35-mL saline flush (2.0 mLÁs 21 ). The TrueX algorithm reconstructed the data into a dynamic series consisting of 29 time frames, using a method similar to one previously described (14) .
Cardiac MRI (CMR). CMR was performed using a 1.5-T Achieva dStream whole-body scanner (Philips) and a 32-channel coil. A survey scan was followed by an electrocardiogram-triggered temporally resolved cine using balanced steady-state free precession during a breathhold. The images were acquired with an 8-mm slice thickness, no slice gap, a 3.1-ms/1.55-ms repetition time/echo time, a 60°flip angle, a 350 • 350 mm field of view, a 352 • 352 acquisition matrix, and 30 phases within a single cardiac cycle. A stack of 16-18 LV short-axis slices was acquired covering the entire left ventricle.

Harms H.J., Stubkjær Hansson N.H., Tolbod L.P., Kim W.Y., Jakobsen S., Bouchelouche K., Wiggers H., Frøkiaer J, & Sörensen J. (2016). Automatic Extraction of Myocardial Mass and Volume Using Parametric Images from Dynamic Nongated PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 57(9).

+ Open protocol

+ Expand

Comparative PET/CT Imaging with Ga-68 Agents

Check if the same lab product or an alternative is used in the 5 most similar protocols

[⁶⁸Ga]Ga-P16-093 and [⁶⁸Ga]Ga-PSMA-11 PET/CT scans in each patient were conducted on different days within 1 week using a dedicated PET/CT scanner (Biograph 64 TruePoint TrueV [Siemens]). The patients were instructed to drink approximately 500 mL of water within 1–2 h and to void immediately before the PET scan. PET/CT images were obtained 50–60 min after an intravenous injection of either [⁶⁸Ga]Ga-P16-093 or [⁶⁸Ga]Ga-PSMA-11 at a dosage of 1.8–2.2 MBq (0.05–0.06 mCi)/kg [17 ]. All patients started with a low-dose CT (120 keV; 50 mAs; 1.3 pitch; 2.5 mm slice thickness; 0.5 s rotation time; estimated radiation dose, 9.0 mGy) for attenuation correction and anatomical localization from the skull vertex to the proximal thigh, followed by a PET scan at 2 min/bed position. The acquired data were reconstructed using ordered-subset expectation maximization (Siemens Biograph 64: 2 iterations, 8 subsets, Gaussian filter of 5 mm in full width at half maximum, 168 × 168 image size).

Wang G., Li L., Zhu M., Zang J., Wang J., Wang R., Yan W., Zhu L., Kung H.F, & Zhu Z. (2023). A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging.

+ Open protocol

+ Expand

Radiolabeling and PET/CT Imaging Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols

The DOTA-CPCR4-2 peptide was purchased from CSBio Co (CA 94025, USA). The radiolabeling of ⁶⁸Ga-pentixafor was performed manually before injection according to the procedures as previously published. ¹⁸F-FDG was synthesized in house with an 11 MeV cyclotron (CTI RDS 111, Siemens, Germany). The PET scans were performed with dedicated PET/CT scanners (Biograph 64 Truepoint TrueV, Siemens, Germany; Polestar m660, SinoUnion, China) from the tip of the skull to the middle thigh. For ¹⁸F-FDG PET/CT, the patients fasted for at least 6 h, and the blood glucose levels were monitored (4.7–6.9 mmol/L) before an injection of ¹⁸F-FDG (5.55 MBq/kg). The PET/CT images (2 min/bed) were acquired with an uptake time of 75.0 ± 13.2 (mean ± SD) min. For ⁶⁸Ga-pentixafor PET/CT, imaging was performed (2–4 min/bed) with an uptake time of 45.9 ± 19.7 min after an injection of 85.1 ± 27.4 MBq of ⁶⁸Ga-pentixafor. The acquired data were reconstructed using the ordered-subset expectation maximization method (Biograph 64: 2 iterations, 8 subsets, Gaussian filter, image size of 168 × 168; Polestar m660: 2 iterations, 10 subsets, Gaussian filter, image size of 192 × 192).

Pan Q., Cao X., Luo Y., Li J, & Li F. (2021). Semi-quantitative measurements of chemokine receptor 4-targeted 68Ga-pentixafor PET/CT in response assessment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. EJNMMI Research, 11, 110.

+ Open protocol

+ Expand

Standardized PET/CT Imaging Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

All PET/CT scans were performed with dedicated PET/CT scanners (Biograph 64 Truepoint True V, Siemens; Discovery 690, GE Healthcare) following the standard protocol. Before ¹⁸F-FDG injection, all patients fasted at least 4-6 hours to ensure that the blood glucose level was less than 120 mg/dL. The PET/CT scans were started approximately 60 minutes after the intravenous administration of ¹⁸F-FDG (5.5 MBq/kg). A low-dose CT scan from the upper thigh to the base of the skull was obtained for attenuation correction and anatomical localization. PET scans were acquired in a 3D mode for 2-3 minutes per bed position.

Hou G., Zhao N., Li F., Jing H, & Zheng R. (2023). Prognostic value of pretreatment 18F-FDG PET/CT metabolic parameters in esophageal high-grade neuroendocrine carcinoma: A bicenter retrospective study. Frontiers in Oncology, 13, 1145557.

+ Open protocol

+ Expand

Radiolabeling and PET/CT Imaging Procedures

Check if the same lab product or an alternative is used in the 5 most similar protocols

The DOTA-FAPI-04 peptide was purchased from CSBio Co (Menlo Park, CA). The radiolabeling of [⁶⁸ Ga]Ga-FAPI-04 was performed manually before injection according to the procedures as previously published [22 (link)]. [¹⁸F]FDG was synthesized in-house with an 11 MeV cyclotron (CTI RDS 111, Siemens, Germany). The PET scans were performed on dedicated PET/CT scanners (Biograph 64 Truepoint TrueV, Siemens, Germany; Polestar m660, SinoUnion, China). For [¹⁸F]FDG PET/CT, the patients fasted for over 6 h, and the blood glucose levels were monitored (4.5–7.8 mmol/L) prior to an injection of [¹⁸F]FDG (5.55 MBq/kg). The PET/CT images (2 min/bed) were acquired with an uptake time of 75.6 ± 15.1 min. For [⁶⁸ Ga]Ga-FAPI-04 PET/CT, imaging was performed (2 min/bed) with an uptake time of 51.2 ± 13.2 min after an injection of 103.6 ± 33.3 MBq [⁶⁸ Ga]Ga-FAPI-04. The PET/CT scan was obtained from the tip of the skull to the crus. The acquired data were reconstructed using the ordered-subset expectation maximization method.

Pan Q., Yang H., Zhou Z., Li M., Jiang X., Li F., Luo Y, & Li M. (2024). [68 Ga]Ga-FAPI-04 PET/CT may be a predictor for early treatment response in rheumatoid arthritis. EJNMMI Research, 14, 2.

+ Open protocol

+ Expand

PET/CT Evaluation of Crural Fractures

Check if the same lab product or an alternative is used in the 5 most similar protocols

All patients were examined using a clinical PET/CT scanner (Biograph 64 TruePoint TrueV, Siemens Medical Solutions, Erlangen, Germany). One bed position (20 cm), centered at the location of the crural fracture/osteotomy, was used. After hydration with 7 deciliters of water 30 minutes prior to the examination, the patient was positioned on the scanning couch as previously described [15 (link)]. A noncontrast, diagnostic CT was performed as described in Table 2 [15 (link)]. A list mode PET acquisition was started simultaneously with the intravenous Na¹⁸F⁻ injection (2 MBq/kg body weight) and continued for 45 minutes. Volumes were reconstructed as described in Table 2 for intervals from injection time to 1, 2, 3, 4, 5, 8, 11, 14, 17, 20, 25, 30, 35, and 45 minutes after injection. These times were chosen as described in Discussion.

Lundblad H., Maguire GQ J.r., Karlsson-Thur C., Jonsson C., Noz M.E., Zeleznik M.P., Jacobsson H, & Weidenhielm L. (2015). Using PET/CT Bone Scan Dynamic Data to Evaluate Tibia Remodeling When a Taylor Spatial Frame Is Used: Short and Longer Term Differences. BioMed Research International, 2015, 574705.

+ Open protocol

+ Expand

Multimodal PET Imaging of CXCR4 Expression

Check if the same lab product or an alternative is used in the 5 most similar protocols

The DOTA-CPCR4-2 peptide was purchased from CSBio Co (CA 94025, USA). The radiolabeling of [⁶⁸Ga]pentixafor was performed manually before injection according to the procedures as previously published [8 (link)]. [¹⁸F]FDG was synthesized in house with an 11 MeV cyclotron (CTI RDS 111, Siemens, Germany).
The PET scans were performed on dedicated PET/CT scanners (Biograph64 Truepoint TrueV, Siemens, Germany; Polestar m660, SinoUnion, China) from the tip of the skull to the middle thigh. For [¹⁸F]FDG PET/CT, patients fasted for over 6 h and the blood glucose levels were monitored (4.4–8.8 mmol/L) prior to an injection of [¹⁸F]FDG (5.55 MBq/kg). The PET/CT images (2 min/bed) were acquired with an uptake time of 76.0 ± 15.8 min (range 50–105 min). For [⁶⁸Ga]pentixafor PET/CT, imaging was performed (2–4 min/bed) with an uptake time of 56.1 ± 22.0 min (range 30–108 min) after injection of 2.8 ± 0.9 MBq (range 1.3–5.0 MBq) [⁶⁸Ga]pentixafor. All patients underwent unenhanced low-dose CT (120 kV, 30–50 mAs) for attenuation correction and anatomical reference. The acquired data were reconstructed using the ordered subset expectation maximization method (Siemens Biograph 64 2 iterations, 8 subsets, Gaussian filter, image size 168 × 168; SinoUnion Polestar 2 iterations, 10 subsets, Gaussian filter, image size 192 × 192).

Pan Q., Luo Y., Zhang Y., Chang L., Li J., Cao X., Li J, & Li F. (2020). Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG. EJNMMI Research, 10, 89.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!